There are a number of positive catalysts on the horizon for Endeavour Mining PLC, according to analysts at Barclays who reiterated that the stock remains its preferred precious metals equity exposure in Europe.
In a note to clients, the analysts highlighted that on May 11, it was revealed that the West Africa-focused gold miner would be included in the MSCI Standard Development Market indices, with the rebalance effective after the market close on May 31.
S&U is still in favour with house broker Peel Hunt, which sees 20% upside to its current 3,150p target price.
Commenting after a brief trading update from S&U ahead of its AGM, the broker said that factors that suppressed growth recently should ease as the year progresses.
S&U PLC (LSE:SUS) expects to get a boost from the new customer duty rules being introduced by UK financial regulator, the Financial Conduct Authority (FCA).
The second-hand car and bridging finance group believes its procedures and processes will be recognised by the FCA and it will gain a competitive advantage over less rigorous rivals.
ANGLE PLC (AIM:AGL, OTCQX:ANPCY), a pioneer of liquid biopsy technology, has announced a significant contract win with Artios Pharma.
Under the deal ANGLE's bespoke DNA Damage Response (DDR) assays will be deployed in a phase I cancer clinical trial led by Artios, slated to conclude by year-end 2024.